Targeted Therapies in Advanced Cutaneous Squamous Cell Carcinoma

The manufacturer has resubmitted an application to the FDA for approval of the drug cosibelimab, which is being investigated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.

During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.

Technology plays a pivotal role in enhancing precision medicine within cancer care.